Related Experiment Video
Updated: Aug 16, 2026

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
Published on: June 13, 2019
Involvement of a cell adhesion molecule, TSLC1/IGSF4, in human oncogenesis
1Tumor Suppression and Functional Genomics Project, National Cancer Center Research Institute, 5-1-1, Tsukiji, Tokyo 104-0045, Japan. ymurakam@gan2.ncc.go.jp
Abstract:
The occurrence of aberrations in cell adhesion is a critical phase in the invasion and metastasis of human cancer. A tumor suppressor gene, TSLC1/IGSF4, from chromosomal region 11q23 was identified in non-small cell lung cancer (NSCLC) by its tumor suppressor activity in nude mice. TSLC1/IGSF4 is expressed in most tissues except for peripheral blood lymphocytes, but it is inactivated in 44% of NSCLC and 30-60% of various cancers, including liver, pancreatic, and prostate cancers, especially in those with invasion or metastasis. Inactivation occurs by two hits: through promoter methylation, and through loss of heterozygosity at the gene locus. TSLC1/IGSF4 encodes an immunoglobulin superfamily cell adhesion molecule and associates with an actin-binding protein, DAL-1/4.1B, and members of the membrane-associated guanylate kinase homologue (MAGuK) group, providing a novel tumor suppressor cascade that is inactivated in more than 80% of NSCLC. TSLC1/IGSF4 appears to be involved in the formation of an epithelial cell structure with DAL-1/4.1B and MAGuK. Furthermore, TSLC1/IGSF4 may act as a tumor antigen recognized by activated NK or CD8+ T cells. These two distinct mechanisms based on homophilic and heterophilic interactions would be responsible for tumor suppression by TSLC1/IGSF4. TSLC1/IGSF4 is ectopically expressed in adult T-cell leukemia (ATL) cells, providing not only a diagnostic marker for ATL, but also a possible therapeutic target against its invasion. The distinct roles of TSLC1/IGSF4 in the oncogenesis of carcinomas and ATL could be due to tissue-specific differences in the downstream cascades, and is a novel concept with respect to cell adhesion in human oncogenesis.
Insights
The TSLC1/IGSF4 gene, a cell adhesion molecule, acts as a tumor suppressor in various cancers, including non-small cell lung cancer. Its inactivation, through methylation or gene loss, promotes cancer invasion and metastasis.
Area of Science:
- Oncology
- Molecular Biology
- Cell Adhesion Research
Background:
- Aberrant cell adhesion is crucial for cancer invasion and metastasis.
- TSLC1/IGSF4, a tumor suppressor gene at chromosomal region 11q23, exhibits activity in non-small cell lung cancer (NSCLC).
- TSLC1/IGSF4 is expressed in most tissues but inactivated in a significant percentage of NSCLC and other cancers, particularly those with metastatic potential.
Purpose of the Study:
- To investigate the role of TSLC1/IGSF4 in cancer, focusing on its tumor suppressor activity and mechanisms of inactivation.
- To explore the association of TSLC1/IGSF4 with cell adhesion molecules and its potential as a tumor antigen.
- To evaluate TSLC1/IGSF4 as a diagnostic marker and therapeutic target in adult T-cell leukemia (ATL).
Main Methods:
- Identification of TSLC1/IGSF4 in NSCLC based on tumor suppressor activity in nude mice.
- Analysis of TSLC1/IGSF4 inactivation through promoter methylation and loss of heterozygosity.
- Investigation of TSLC1/IGSF4 interactions with DAL-1/4.1B and MAGuK proteins.
- Assessment of TSLC1/IGSF4 expression in adult T-cell leukemia (ATL) cells.
Main Results:
- TSLC1/IGSF4 inactivation occurs via promoter methylation and loss of heterozygosity, affecting 44% of NSCLC and 30-60% of other cancers.
- TSLC1/IGSF4 encodes an immunoglobulin superfamily cell adhesion molecule that forms a tumor suppressor cascade with DAL-1/4.1B and MAGuK proteins.
- TSLC1/IGSF4 is implicated in epithelial cell structure formation and may function as a tumor antigen recognized by NK or CD8+ T cells.
- Ectopic expression of TSLC1/IGSF4 in ATL cells suggests its utility as a diagnostic marker and therapeutic target.
Conclusions:
- TSLC1/IGSF4 functions as a critical tumor suppressor through distinct homophilic and heterophilic interaction mechanisms.
- Inactivation of the TSLC1/IGSF4 tumor suppressor cascade contributes to cancer progression, particularly in NSCLC.
- TSLC1/IGSF4 holds potential as a diagnostic marker and therapeutic target for ATL, with distinct roles in oncogenesis possibly due to tissue-specific downstream effects.
Related Concept Videos
Intracellular Signaling Affects Focal Adhesions
Some...
Immunoglobulin-like Cell Adhesion Molecules
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
Cell Adhesion Molecules - Types and Functions
CAM Families
The Integrin family of proteins is primarily involved in a...
Cell Adhesion Molecules - Types and Functions
CAM Families
The Integrin family of proteins is primarily involved in a...
Cadherins in Tissue Organization
Cell Sorting During Development
Cell sorting plays an...
Activation of Integrins
In "outside-in signaling," external factors in the extracellular space bind to exposed ligand binding sites on integrins. This causes the inactive protein to undergo a conformational change to become active. Integrins are often clustered on the cell membrane. Repetitive and regularly spaced ligand binding events provide an effective stimulus.

